Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Multicenter Study Evaluating the Feasibility, Safety, and Efficacy of Point-of-care Manufactured GLPG5101 (19CP02) in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Next Previous
Trial Profile

A Phase I/II, Multicenter Study Evaluating the Feasibility, Safety, and Efficacy of Point-of-care Manufactured GLPG5101 (19CP02) in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GLPG 5101 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications B-cell lymphoma; Burkitt's lymphoma; CNS cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Richter's syndrome
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms Atalanta-1
  • Sponsors Galapagos NV

Most Recent Events

  • 15 Sep 2025 Planned number of patients changed from 250 to 274.
  • 18 Jun 2025 Results presented in the Galapagos NV media release.
  • 18 Jun 2025 According to a Galapagos NV media release, results from Cohort 3 of this trial were presented at the 18th International Conference on Malignant Lymphoma (ICML).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top